

1 **The impact of short duration, high intensity exercise on cardiac troponin release**

2

3 **Keith P George¹, Marie Clare Grant^{2,3}, Bruce Davies⁴ and Julien S Baker²**

4

5 ¹ *Research Institute for Sport and Exercise Sciences, School of Sport and Exercise Sciences,*

6 *Liverpool John Moores, Liverpool, L3 3AF*

7 ² *Institute of Clinical Exercise and Health Science, Exercise Science Research Laboratory,*

8 *School of Science, Faculty of Science and Technology, University of the West of Scotland,*

9 *Hamilton, Scotland, ML3 0JB, UK.*

10 ³ *Division of Sport and Exercise Sciences, School of Social & Health Sciences, Abertay*

11 *University, Bell Street, Dundee. DD1 1HG, UK.*

12

13 ⁴ *Sport, Health and Exercise Science Research Unit, Faculty of Life Sciences and Education,*

14 *University of South Wales, Treforest, CF37 1DL.*

15

16 **Correspondence should be addressed to Julien S Baker; jsbaker@uws.ac.uk**

17 **Abstract**

18 Whilst there is substantial evidence of cardiac troponin (cTnI) appearance during or
19 subsequent to endurance exercise the database with short duration, high intensity exercise is
20 extremely limited. The reproducibility of any exercise-related cTnI response is unclear at this
21 point. Consequently, we recruited 18 healthy young male adults who undertook two all-out
22 30 s cycle sprints separated by 7 days. cTnI, blood lactate and catecholamine concentrations
23 were measured before, immediately after and 24 hr after each bout. Cycle performance, heart
24 rate and blood pressure responses to exercise were also recorded. Whilst cycle performance
25 was modestly elevated in the second trial (6.5% increase in peak power output) there was no
26 difference in the cardiovascular, lactate or catecholamine response to the two cycle trials.
27 cTnI was not significantly elevated from baseline through recovery (Trial 1: 0.06 ± 0.04 ng.ml⁻¹,
28 0.05 ± 0.04 ng.ml⁻¹, 0.03 ± 0.02 ng.ml⁻¹ Trial 2: 0.02 ± 0.04 ng.ml⁻¹, 0.04 ± 0.03 ng.ml⁻¹,
29 0.05 ± 0.06 ng.ml⁻¹) in either trial. Very small within subject changes were not significantly
30 correlated between the two trials ($r=0.06$; $p>0.05$). We can conclude that short duration, high
31 intensity exercise does not elicit a clinically relevant response in cTnI and any small
32 alterations likely reflect the underlying biological variability of cTnI measurement within the
33 participants.

34

35

36 **Introduction**

37 Recent scientific literature is replete with observations of elevated cardiac biomarkers during
38 and after prolonged endurance exercise [1, 2, 3, 4]. Different cardiac biomarkers reflect
39 different pathological and/or physiological processes but most attention in the sports
40 medicine literature has been paid to the exercise-related appearance of cardiac troponins
41 (cTnI and/or cTnT). cTnI/T are recognised as highly tissue-specific biomarkers of myocyte
42 cell insult [5] and are important in clinical decision making when acute cardiac events are
43 suspected [6]. An elevation in cTn either during or after exercise has, consequently,
44 generated both interest and concern in athletes, scientists and clinicians [4].

45

46 An exercise-associated elevation in cTnI and/or cTnI has been reported after endurance
47 events lasting a couple of hours [7] through to multiple days [8]. The mechanism(s)
48 associated with exercise-related appearance of cTnI or T have not been proven but likely
49 relate to the unremitting cardiovascular work and associated changes in metabolic milieu of
50 the cardiomyocytes [4]. Most available data related to exercise-associated increases in cTnI
51 or cTnT have been produced from field-based studies with simple pre-post blood draws [4].
52 This has limited our ability to interpret this data and the exact role that exercise plays. A
53 unique study was completed by Middleton et al. (2008) [9] whereby 9 marathon runners
54 completed a treadmill-based marathon run with blood taken every 30 min. This study
55 demonstrated an elevation in cTnT in every single runner with some changes noted as early
56 as 30 min after the start of exercise. In another study by the same group, cTnI was elevated in
57 most runners completing a high intensity, steady state 30 min run [10]. Taken together these
58 data would suggest that exercise-associated elevations of cTn are likely very common and
59 may occur very quickly with exercise. Despite this we still require additional data to
60 determine if a cTn-positive response is produced in response to exercise *per se*. Neither is it

61 clear whether very high exercise intensity (with concomitant shortened durations) may
62 mediate cTn release [4]. Finally, to date there is limited evidence as to whether the cTn
63 response to any exercise bout is a reproducible phenomenon.

64

65 Consequently, the aim of the current study was to assess; a) the appearance of cTnI after a
66 short bout (30 s) of “all-out” intense exercise, and b) to determine the stability of any exercise
67 related cTnI release in response to repeated bouts of high intensity exercise separated by 7
68 days recovery.

69

70 **Materials and methods**

71 *Subjects and design*

72 Eighteen apparently healthy, physically active, male university students volunteered
73 to participate (mean±SD age: 23±2.0 yr; body mass: 75.3±11 kg; stature 175.8±5.7 cm. The
74 study was approved by the University Ethics Committee and all participants provided written
75 informed consent form. All participants were full familiarised to the exercise test. The study
76 design was a repeated measures approach to biomarker assessment before and after 2 high
77 intensity exercise trials, separated by 7 days. For six weeks prior to data collection, and
78 throughout the study, participants maintained normal physical activity and dietary habits and
79 refrained from macro and micro-nutrient supplementation and/or the use of pharmaceutical
80 agents. Repeated assessments of cardiac biomarkers were made before, immediately after
81 and 24 h after each exercise bout.

82

83 *Baseline measures*

84 At baseline body mass, stature and body composition was determined using a
85 calibrated balanced weighing scales (Seca, UK), stadiometer (Seca, UK) and underwater

86 weighing procedures, respectively. Body density was assessed as described previously [11].
87 Relative body fat was estimated from body density [12]. Residual lung volume was measured
88 using the simplified oxygen re-breathing method [13]. Fat free mass (FFM) was determined
89 by subtracting fat mass from total body mass.

90

91 *The Acute Exercise Test*

92 Participants performed 2 all-out 30 s cycle ergometer tests (Monark, 864, Monark-Crescent
93 AB, Varberg, Sweden). A force velocity test was performed one week prior to the 30s cycle
94 ergometer test to determine optimal resistive forces based on total body mass (TBM) and fat free mass
95 (FFM). Briefly, the test consisted of six short maximal sprints (6-8 s) against randomly assigned
96 resistive forces (70, 75, 80, 85, 90 and 95 g.kg⁻¹). Successive exercise bouts were separated by a 5 min
97 rest period. The resistive force that produced the highest PPO value for both TBM and FFM protocol
98 was used in the 30s test. Reliability of the optimal resistive force obtained for both TBM and FFM
99 protocol was determined using test retest methods. The order of the two 30s tests were
100 randomised and separated by 7 days. The cycle ergometer was set-up and calibrated in the
101 same way for all tests [14]. Saddle heights were adjusted to accommodate partial knee flexion
102 of between 170° to 175° (with 180° denoting a straight leg position) during the down stroke
103 and were consistent between repeated tests. Feet were firmly supported by toe clips and
104 straps. All subjects were instructed to remain seated during the test and were verbally
105 encouraged to perform maximally. All participants performed a standardised 5 min warm up
106 prior to experimental data collection [15]. Participants were given a rolling start at 60 rpm for
107 a 5 s period prior to resistive force application. On the command 'go', the subjects began to
108 pedal maximally, the resistive force applied simultaneously, and data capture initiated.
109 Indices of performance were calculated from flywheel revolutions using an inertia corrected
110 computer program [14]. Data transfer was made possible using a mounted sensor unit and
111 power supply attached to the fork of the ergometer located opposite the flywheel. The

112 sampling frequency of the sensor was 18.2 Hz. Validity of the cycle ergometer as a test of
113 muscle power has been reported as $r = 0.93$ [16]. Heart rate was recorded throughout exercise
114 using a short range telemetry system (Sport Tester 3000, Polar Electro Finland). Peak power
115 output (PPO), the highest 1-s value of power attained during each 30-s sprint as well as mean
116 power output (MPO), the average power output for the 30-s period, were recorded for each
117 trial. A fatigue index, the drop in power from a maximal to a minimal value over the 30 s was
118 expressed as a percentage and total work done was estimated across the 30 s sprint.

119

120 *Blood Sampling and analysis*

121 Duplicate blood samples were collected at the same time of day and by the same
122 investigator in all trials in an attempt to control for biological and between subject variation
123 [17]. In an attempt to control for plasma volume changes, all resting samples were taken
124 following 30 min of supine rest. The immediate post exercise samples were taken with
125 subjects placed in a supine position on a clinical couch to minimise the risk of fainting.
126 Capillary blood samples were collected from the right ear lobe and were analysed
127 immediately for Haematocrit (Hawksley Micro haematocrit reader, Sussex, UK),
128 haemoglobin (Haemocue, Sussex, UK) and blood lactate concentration (Analox P-LM5,
129 London, UK). Changes in plasma volume were calculated from haematocrit and
130 haemoglobin using the equations of Dill and Costill (1974) [18]. This data was used to adjust
131 absolute data of biomarkers for any alterations in plasma volume.

132 At the same time venous blood samples were collected from an antecubital forearm
133 vein using the Vacutainer System (Becton Dickinson, Rutherford, NJ, USA) and placed
134 immediately on ice. Samples were centrifuged at 3,500 rpm for 10 min. Serum was then
135 extracted and placed into plastic storage containers and stored at -80°C .

136

137 Adrenaline and noradrenaline concentrations were determined using the Gilson
138 ASTED.XL (Anachem; Luton, Beds, UK), a fully automated sample processing system, with
139 an improved sample handling system that included dialysis and sample clean-up on a strong
140 cation trace-enrichment cartridge. The catecholamines were separated by reverse phase ion-
141 pair chromatography. Calibrations were run every tenth and controls, every fifth sample.
142 Coefficients of variation ranged between 1.1% and 9.3%.

143

144 Cardiac Troponin I (cTnI) concentrations were determined using the Chiron
145 Diagnostics ACS: 180[®] Automated Chemiluminescence Systems (Medfield, MA, U.S.A.).
146 The detection limit for cTnI was set at 0.06 ug.L⁻¹. The coefficient of variation was
147 established at 3.5%.

148

149 *Statistical Analysis*

150 Data were analysed using a computerised statistical package (SPSS Version 2,
151 Chigaco, USA) using parametric statistics. Significance was set at the $P < 0.05$ level.
152 Confirmation that all dependent variables were normally distributed was assessed via
153 repeated Kolmogorov-Smirnov tests. Changes in exercise performance and peak HR data
154 between trials were compared using repeated measures ANOVA. Blood borne parameters
155 and cTnI data were compared via repeated measures 2-way ANOVA (TIME: pre;
156 immediately; and 24 h post exercise; TRIAL: TBM, FFM). Following simple main and
157 interaction effects, Bonferroni-corrected paired samples *t*-tests were applied to make
158 *posteriori* comparisons of the effect of time at each level of the trial factor. The delta change
159 in cTnI from baseline to immediately post-exercise was compared between trials using a
160 intra-class correlation test.

161

162 **Results**

163 Values for performance data and peak heart rate generated during the study for the
164 two 30-s all out cycling trials are presented in Table 1. Although there was a small but
165 significantly higher PPO with the FFM trial (c. 6.5%, $P < 0.05$), all other performance test
166 data were not different between trials ($P > 0.05$). Resting HR (68 beats.min⁻¹) was the same
167 prior to both trials and peak HR attained was not different between trials. There was a
168 significant PVL between baseline and end-exercise ($P < 0.05$) that was not different between
169 trials ($P > 0.05$; Table 2), with a return to baseline at 24 h post-test in both trials. This data
170 was used to correct data for blood borne parameters and biomarkers. Of note the blood lactate
171 concentrations rose with exercise ($P < 0.05$) and declined to baseline at 24 h post trial but
172 these changes were similar between trials ($P > 0.05$; Table 2). Biomarkers of sympathetic
173 neural activation, adrenaline and noradrenaline, were elevated post-exercise in both trials (P
174 < 0.05 ; Table 2) and returned to baseline at 24 h post exercise. Again the kinetics of
175 adrenaline and noradrenaline change with all-out 30-s exercise was consistent between trials
176 ($P < 0.05$).

177

178

179

180

181

182

183

184

185

186

187

188 Table 1. Exercise performance and HR data for the cohort over both 30 s trials.

Parameter	Trial	Mean \pm SD
PPO (W)	1-TBM	953 \pm 111
	2-FFM	1020 \pm 130 *
Time to PPO (s)	1-TBM	4.1 \pm 3.1
	2-FFM	3.5 \pm 1.5
MPO (W)	1-TBM	535 \pm 81
	2-FFM	512 \pm 86
FI (%)	1-TBM	42 \pm 8
	2-FFM	38 \pm 10
Total Work (J)	1-TBM	16050 \pm 1828
	2-FFM	15369 \pm 1975
Peak HR (beats.min ⁻¹)	1-TBM	177 \pm 8
	2-FFM	175 \pm 5

189 TBM-total body mass, FFM-fat free mass, PPO-peak power output, MPO-mean power output, FI-fatigue index,

190 HR-heart rate, * significantly different from the other trial ($P < 0.05$).

191

192

193

194

195

196

197

198 Table 2. Blood borne biomarker data for both short duration high intensity cycle trials

Parameter	Trial	Baseline	Immediate Post-Ex	24 h Post-Ex
PVL (%)	1-TBM	-	-12.2 ± 5.8	4.3 ± 10.0
	2-FFM	-	-12.6 ± 6.9	5.1 ± 6.2
BLa (mmol.l ⁻¹)*	1-TBM	0.5 ± 0.7	9.0 ± 1.2	0.6 ± 0.6
	2-FFM	1.1 ± 0.9	9.3 ± 1.4	0.7 ± 0.8
A (nmol.l ⁻¹)*	1-TBM	0.3 ± 0.1	2.8 ± 1.6	0.3 ± 0.1
	2-FFM	0.2 ± 0.1	3.3 ± 1.9	0.3 ± 0.1
NA (nmol.l ⁻¹)*	1-TBM	1.3 ± 0.4	19.1 ± 7.9	1.5 ± 0.5
	2-FFM	1.7 ± 0.4	20.0 ± 9.6	1.3 ± 0.4


199 PVL-plasma volume loss, BLa-blood lactate concentration, A-adrenaline, NA-noradrenaline, Ex-exercise, *-
 200 significant main effect of time, but no significant main effect of trial or interaction.

201

202 Mean cohort data for cTnI are presented in Figure 1. In both trials there was no
 203 significant main effect of sample time, trial or interaction effect. Cohort data can mask small
 204 individual changes and consequently we plotted delta cTnI from baseline to immediately
 205 post-exercise from both trials in Figure 2. This Figure demonstrates that any individual
 206 change is very small and largely unpredictable from trial to trial ($r=-0.02$; $P > 0.05$).


207

208



209

210 Figure 1. Group mean data for cTnI in Trial 1 and 2 at baseline, immediately post-exercise
 211 and 24 h post-exercise.



212

213 Figure 2. Scatterplot of delta cTnI responses from pre-exercise to post-exercise for trial 1 and
 214 2.

215 **Discussion**

216 The key novel finding from this study is that short duration, high intensity cycling bouts (30
 217 s) does not elicit a statistically or clinically significant increase in circulating cTnI during
 218 immediate or late (24 hr post) recovery. Any small individual changes in response to exercise
 219 are not consistent between trials and likely reflects the small biological variance in the cTnI
 220 assay within a young, healthy cohort.

221

222 The extant sports medicine literature is replete with descriptive evidence of a rise in cTnI or
223 cTnT during or after bouts of endurance exercise [4]. This phenomenon has been reported in
224 different participant groups from the elite athlete to relatively untrained “weekend warrior”
225 [e.g. 7, 19], from young adolescents to those in later life [e.g. 20, 21], across a range of
226 exercise bouts [22, 23]. What has characterised nearly all studies to date has been the
227 employment of endurance activity as it has been assumed that any cTn release with exercise
228 is due to some mechanism associated with the unremitting haemodynamic or metabolic stress
229 of prolonged activity on the heart. Recently, two studies have shed new and interesting
230 insights into exercise-related cTn appearance. Firstly, Middleton et al. (2008) [22] assayed
231 for cTn every 30 min during a treadmill-based marathon run and reported early (at 30 min)
232 elevation of cTn in some runners and an exercise-related cTn rise in all runners at some point
233 during the marathon. The same group then employed a high intensity 30 min run and
234 observed a rise in cTn in most participants [10]. Taken together it was hypothesised that a
235 cTn rise with exercise was potentially an inevitable phenomenon that would likely be
236 physiological in nature. The current study was conceived as an extension to the work of
237 Middleton et al. (2008) [22] and Shave et al. (2010b) [10] to determine if any exercise (per
238 se), even 30 s of high intensity cycling, could act as a stimulus to induce cTn changes in the
239 circulation. Whilst exercise may be a potent stimulus for cTn appearance in the systemic
240 circulation, the lack of a statistical or clinically significant rise in cTn after a 30s all-out cycle
241 trial in the current study would suggest that the total volume of exercise undertaken (30 s all-
242 out) placed insufficient stress on the heart. Despite a rapid acceleration of HR with 30 s of all
243 out cycling, there is a subsequent quick deceleration of HR suggesting that the total
244 myocardial work and oxygen demand is very low in comparison to previous studies that have
245 employed endurance exercise, over many hours, days and even weeks [4].

246

247 A secondary aim from this study was to determine if the cTn response to a short duration,
248 high intensity cycle trial was consistent and repeatable if the exposure was repeated after 7
249 days. The repeatability of the exercise-related cTn response has received scant attention [20]
250 but may be insightful when addressing the potential impact or mechanisms involved in cTn
251 appearance with exercise. At one level the cTn response to the exercise intervention
252 employed was highly consistent as there was no significant rise in cTn after both cycling
253 trials. This consistency in a “null” response adds to the apparent repeatability in the “cTn-
254 positive” response to exercise in a mixed adult/adolescent running study [20]. A secondary,
255 within subject analysis in the current study assessed the consistency of the very small changes
256 in cTn observed post-exercise. Not surprisingly the correlation of delta responses was very
257 low ($r=0.06$) given the small absolute and relative changes. This likely provides some insight
258 into the very low levels of biological variability of this cTn assay in these participants’
259 undertaking short bouts of activity.

260

261 The implications from this study are straightforward. Short bursts of high intensity activity
262 do not seem to result in an elevation in cTn either immediately or during later recovery from
263 exercise suggesting this type of exercise bout does not activate the mechanism(s) required to
264 elicit a statistically or clinically meaningful cTn response. Within the applied sports
265 medicine setting the appearance of large cTn increase (above clinical cut-offs 0.2 ng.ml^{-1}) in
266 any participants or athletes with a recent history of exercise of less than 30 min should raise a
267 potential red flag for further clinical investigation.

268

269 As with all studies there are some limitations of note that should be followed up in on-going
270 studies. The data in the current study pertain only to young, healthy male participants. Given

271 that there may be different exercise-cTn responses in different participant populations this
272 study should be replicated in broader groups (age, sex, fitness status). Future work may
273 employ blood samples in recovery to provide conclusive evidence of a lack cTn response to
274 short bouts of physical activity.

275

276 In conclusion, a short duration, high intensity cycle trial does not result in an elevation of
277 cTnI immediately post-exercise or later during recovery (24 hr). The lack of a cTn response
278 was consistent over two cycling trials suggesting the overall response was repeatable. Small
279 between subject variance in cTn response to the exercise stimulus was clinically meaningless
280 and likely reflects a low level of biological variability in this assay in the current participants.

281

282

283 **References**

284 [1] R. Shave, G. Atkinson, G. Whyte, et al., "Exercise-Induced Cardiac Troponin T
285 release: A Meta-Analysis," *Medicine and Science in Sport and Exercise*, vol. 39, pp.
286 2099-2106, 2007a.

287

288 [2] R. Shave, K.P. George, and D. Gaze, "The influence of exercise upon cardiac
289 biomarkers: A practical guide for clinicians and scientists," *Current Medicinal
290 Chemistry*, vol. 14, pp. 1427-1436, 2007b.

291

292 [3] J. Scharhag, K.P. George, R. Shave, et al., "Exercise-Associated Increases in Cardiac
293 Biomarkers," *Medicine and Science in Sport and Exercise*, vol. 4, pp. 1408-1415,
294 2008.

295

- 296 [4] R. Shave, A. Baggish, K. George, et al., “Exercise-induced Cardiac Troponin
297 Elevation: Evidence, Mechanisms, and Implications,” *Journal of American College of*
298 *Cardiology*, vol, 56, pp. 169-176, 2010a.
- 299
300 [5] P.O Collinson, F.G Boa, and D.C. Gaze, “Measurement of cardiac troponins,” *Annals*
301 *of Clinical Biochemistry*, vol, 38, pp. 423-449, 2008.
- 302
- 303 [6] K. Thygesen, J.S. Alpert, and H.D White, “Joint ESC/ACCF/AHA/WHF Task Force
304 for the Redefinition of Myocardial Infarction. Universal definition of myocardial
305 infarction,” *Journal of American College of Cardiology*, vol, 50, pp. 2173-2195,
306 2007.
- 307
- 308 [7] R. Shave, G. Whyte, K.P. George, et al.,” Prolonged exercise should be considered
309 alongside typical symptoms of AMI when evaluating elevations in cardiac troponin
310 T,” *Heart*, vol, 91, pp. 1219-1220, 2005.
- 311
- 312 [8] K. William, W. Gregson, C. Robertson, et al., “Alterations in left ventricular function
313 and cardiac biomarkers as a consequence of repetitive endurance cycling,” *European*
314 *Journal of Sport Science*, vol. 9, pp. 97-105, 2009.
- 315
- 316 [9] N. Middleton, K.P. George, G.P. Whyte, et al., “Cardiac Troponin T release is
317 stimulated by endurance exercise in healthy humans,” *Journal of American College of*
318 *Cardiology*, vol. 52, pp. 1813-1814, 2008
- 319

- 320 [10]R. Shave, P. Ross, D. Low, et al., “Cardiac troponin I is released following high
321 intensity short-duration exercise in humans,” *International Journal of Cardiology*, vol.
322 145, pp. 337-339, 2010b.
- 323
- 324 [11]A.R. Behnke, and J.H. Wilmore, “Evaluation and regulation of body build and
325 composition,” pp. 20-24, Prentice-Hall, Englewood Cliffs, NJ, 1974.
- 326
- 327 [12]W.E. Siri, “Gross composition of the body,” in *Advances in Biological and Medical*
328 *Physics*, J.H. Lawrence, and C. A Tobias, Eds., pp. 239-280, Academic Press, New
329 York, 1956.
- 330
- 331 [13]J.H. Wilmore, P.A. Vodak, R.B. Parr, et al., “Further simplification of a method for
332 determination of residual lung volume,” *Medicine and Science in Sport and Exercise*,
333 vol.12, pp. 216-218, 1979.
- 334
- 335 [14]S. Coleman, “Corrected Wingate Anaerobic Test Cranlea Users Handbook,” Cranlea
336 and Co, England, 1996.
- 337
- 338 [15]A. Jaskolska, P. Goossens, B. Veenstra, et al., “Comparison of treadmill and cycle
339 ergometer measurements of force-velocity relationships and power output.
340 *International Journal of Sports Medicine*, vol. 20, pp. 192-197, 1999.
- 341
- 342 [16]J. Patton, M. Murphy, and F. Frederick. “Maximal power outputs during the
343 Wingate anaerobic test,” *International Journal of Sports Medicine*. 1985; vol. 6, pp. 82-
344 85, 1985.

345

346 [17] T. Reilly, and G.A. Brooks, "Investigation of circadian rhythms in metabolic
347 responses to exercise," *Ergonomics*, vol. 25, pp. 1093-1197, 1982.

348

349 [18] D.B. Dill, and Costill D.L. "Calculation of the percentage changes in volumes of
350 blood, plasma and red cells in dehydration," *Journal of Applied Physiology*, vol. 37, pp.
351 247-248, 1974

352

353 [19] A. Bonetti, F. Tirelli, R. Albertini, et al., "Serum cardiac troponin T after repeated
354 endurance exercise events," *International Journal of Sports Medicine*, vol. 17, pp. 259-
355 262, 1996.

356

357 [20] Y. Tian, J. Nie, C. Huang, et al., "The kinetics of highly sensitive cardiac troponin T
358 release after prolonged treadmill exercise in adolescent and adult athletes," *Journal of*
359 *Applied Physiology*, vol. 113, pp. 418-425, 2012.

360

361 [21] T.M. Eijssvogels, M.D. Hoogerwerf, M.F. Maessen, et al., "Predictors of cardiac
362 troponin release after a marathon," *Journal of Science and Medicine in Sport*, pp.
363 S1440-2440, 2014.

364

365 [22] N. Middleton, K. George, G. Whyte, et al., "Cardiac troponin T release is stimulated
366 by endurance exercise in healthy humans," *Journal of American College of Cardiology*,
367 vol. 52, pp. 1813-1814, 2008.

368

369 [23]J.M. Scott, B.T Esch, R. Shave, et al., “Cardiovascular consequences of completing
370 a 160-km ultramarathon,” *Medicine and Science in Sports and Exercise*, vol. 41, pp.
371 26-34, 2009.

372

373 [24]Y. Tian, J. Nie, K.P. George, et al., “Reproducibility of cardiac biomarkers response
374 to prolonged treadmill exercise,” *Biomarkers*, doi: 10.3109/1354750X.2014.880855,
375 2014.

376